About Rallybio

Rallybio is a privately-held, development-stage biotechnology company focused on bringing life-transforming medicines to patients with devastating and rare disorders. The company is built around a seasoned team of biopharma industry leaders with extensive research, development, and business experience.

With offices located in the University of Connecticut’s Technology Incubation Program campus, Rallybio is continuing its extensive drug acquisition and development activities.  The company has built an impressive team uniquely capable of effectively identifying, attaining and developing assets that are aligned with Rallybio’s mission.  The team is working tenaciously to continue expanding and advancing its pipeline of therapies that will transform the lives of patients with severe and rare disorders.

Named as one of the “Fierce 15” Biotech Companies of 2018, Rallybio was recognized by FierceBiotech as among “the most promising private biotech startups”. Rallybio has secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.

Rallybio Team

Founded by seasoned biopharma industry leaders with extensive research, development, and business experience, Rallybio has built an impressive team uniquely capable of effectively identifying, attaining and developing assets that are aligned with Rallybio’s mission.

Rallybio Board of Directors

Ron Hunt

Ron is a Managing Director at New Leaf Venture Partners, and focuses on early to late stage investments in biopharmaceuticals.  Ron was one of the founders of New Leaf in 2005, and today has over two decades of experience investing in, and building, companies focused on developing novel medicines that address important unmet medical needs.  Prior to his start in venture capital in 1998, Ron was a strategy and operations consultant to clients in the pharmaceutical and medical device industries. His experience also includes a number of sales and marketing positions with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (MBA) and Cornell University (B.S.).

Martin Mackay, PhD

Martin is a co-founder of Rallybio, and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca and Alexion.  Martin obtained a First Class Honours Degree in microbiology from Heriot-Watt University and his PhD in molecular genetics from the University of Edinburgh. He is currently a member of the Board of Directors of Charles River Laboratories and Novo Nordisk, and is a Senior Advisor at New Leaf Ventures.  Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.

Kush M. Parmar, MD PhD

Kush is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Akouos, Arvinas (NASDAQ: ARVN), Entrada, Homology (NASDAQ: FIXX), and Vor Biopharma. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Audentes (NASDAQ: BOLD), Envoy (acquired by Takeda) and scPharmaceuticals (NASDAQ: SCPH). Dr. Parmar serves on the Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an AB in Molecular Biology and Medieval Studies from Princeton University, a PhD in Experimental Pathology from Harvard University and an MD from Harvard Medical School. Dr. Parmar is based in the Boston, MA office.

Timothy Shannon, MD

Timothy is a Venture Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies Arvinas (NASDAQ: ARVN), IDEAYA Biosciences, Nextcure, Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation. Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine. Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a bachelor’s in Chemistry from Amherst College.